Key terms
About CRVS
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CRVS news
Mar 29
4:25am ET
Hold Rating Maintained for Corvus Pharmaceuticals Amid Clinical Delays and Financing Concerns
Mar 21
2:01am ET
Corvus Pharmaceuticals: Insider Ownership Raises Power Concentration Concerns
Mar 20
6:24am ET
Corvus Pharmaceuticals price target lowered to $7 from $8 at Oppenheimer
Mar 19
4:22pm ET
Corvus to initiate Phase 1 trial of soquelitinib for AD in Q2
Mar 19
4:15pm ET
Corvus Pharmaceuticals reports Q4 EPS (14c) vs. (21c) last year
Mar 19
8:06am ET
Options Volatility and Implied Earnings Moves Today, March 19, 2024
Feb 12
8:31am ET
Corvus Pharmaceuticals presents preclinical data for soquelitinib
Feb 08
4:31pm ET
FDA grants Corvus Pharmaceuticals’ Soquelitinib ODD for PTCL treatment
Feb 07
5:59pm ET
Corvus Pharmaceuticals’ treatment of T-cell lymphoma gets FDA orphan designation
No recent press releases are available for CRVS
CRVS Financials
Key terms
Ad Feedback
CRVS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CRVS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
